Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #119754 on Biotech Values
DewDiligence
05/10/11 2:42 PM
#119756 RE: jb_118 #119754
A biobetter might be less lucrative than a biosimilar if the former were only marginally better and the latter were substitutable, especially if a biobetter has to generate an entire safety/efficacy package and go through the BLA approval process.